D-1164-2017 Class III Terminated

Recalled by Pfizer Inc. — New York, NY

FDA drug recall D-1164-2017 was initiated by Pfizer Inc. on Aug 4, 2017 and is designated Class III. Reason for recall: Failed Dissolution Specifications The recall status is terminated (terminated Apr 11, 2019). Affected quantity: 11,790 bottles.

Recall details

Product Type
Drugs
Report Date
Sep 27, 2017
Initiation Date
Aug 4, 2017
Termination Date
Apr 11, 2019
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
11,790 bottles

Product description

Quillivant XR methylphenidate HCl, for extended-release oral suspension, 750mg/150 mL total volume (When constituted with 131 mL of water, 25 mg/5 mL (5 mg/mL) when reconstituted, Rx Only, Distributed by Nextwave Pharmaceuticals, Inc. A subsidiary of Pfizer Inc., New York, NY 10017, Manufactured by Tris Pharma, Inc., Monmouth Junction, NJ 08852, NDC 24478-200-25.

Reason for recall

Failed Dissolution Specifications

Distribution pattern

Nationwide

Code information

Lot # 03216047A Exp. 02/18

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-1164-2017
openFDA file date
Nov 16, 2026
Loaded by RegDataLab
Nov 17, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-1164-2017. Report a data issue: hello@regdatalab.com.